News

Pharmaceutical and Medical Device Global Supply Chains Under a Microscope: Understanding and Managing the Growing Risks

June 25, 2020
Coronavirus: Life Sciences and Healthcare Regulatory Webinar
Language

Even prior to the COVID-19 pandemic, pressures were building on the life sciences industry to address vulnerabilities in drug, biologic and medical device supply chains. While the industry's enormous contributions to the pandemic response have been lauded, the complexities and concerns emerging in the pandemic—including drug and device shortages, challenges in rapid countermeasure development and deployment, and geopolitical/trade tensions—all point to a continued paradigm shift in the way governments think about—and regulate—biomedical product supply chains. In this webinar, we outline current vulnerabilities in these supply chains and provide regulatory frameworks, international perspectives and practical methods for addressing them.

To help our clients navigate the coronavirus (COVID-19) crisis, Arnold & Porter has established a Coronavirus Task Force covering a wide range of issues and challenges. Subscribe to our "Coronavirus (COVID-19)" mailing list to receive our latest client Advisories and register for upcoming webinars.

Meet the Speakers

Daniel A. Kracov
Partner
Arnold & Porter
Andrew Shaoyu Chen
Partner
Arnold & Porter
Mahnu V. Davar
Partner
Arnold & Porter
Howard Sklamberg
Partner
Arnold & Porter
Lincoln Tsang
Partner
Arnold & Porter
Subscribe
Subscribe Link

Email Disclaimer